Is it possible to ensure COVID19 vaccine supply by using plants?

IF 2.1 Q4 CELL BIOLOGY

Nucleus (India) Pub Date : 2021-01-01 Epub Date: 2021-07-02 DOI:10.1007/s13237-021-00361-4

Anirban Bhar

{"title":"Is it possible to ensure COVID19 vaccine supply by using plants?","authors":"Anirban Bhar","doi":"10.1007/s13237-021-00361-4","DOIUrl":null,"url":null,"abstract":"Any disease that spreads quickly and crossed the geographical barrier is termed as pandemic. After the initial occurrence of Covid-19 from China, World Health Organization had declared novel corona viral outbreak as pandemic on March, 2020. Since then, COVID-19 continued to devastate people all around the world. Human civilization has witnessed one of its greatest crises by facing 180 million of confirmed cases with 38.9 lakh deaths across the world till end of June 2021. India alone contributes 30 million of positive cases and has lost 3.92 lakh valuable lives (data as on 24th of June 2021 from CSSEGIS and Data (http://github.com/CSSEGISandData/COVID-19); (the number increases in each day). Bio-medical experts from all around the world are working tirelessly to limit the disease and find potential cures for this viral infection. Vaccination is the most effective strategy to prevent the spread of any viral disease. Virologists have developed some effective vaccines, but production or supply lags far behind the present demand across the globe. Plant-derived vaccines (PDVs) based on modified virus like particles (VLPs) can be a feasible alternative in this case. A summarized account about the efficacy of the first plant-derived Covid 19 vaccine, CoVLP is discussed. PDVs and VLPs are also reviewed briefly, along with their benefits and drawbacks.","PeriodicalId":53176,"journal":{"name":"Nucleus (India)","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13237-021-00361-4","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nucleus (India)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13237-021-00361-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/2 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

Any disease that spreads quickly and crossed the geographical barrier is termed as pandemic. After the initial occurrence of Covid-19 from China, World Health Organization had declared novel corona viral outbreak as pandemic on March, 2020. Since then, COVID-19 continued to devastate people all around the world. Human civilization has witnessed one of its greatest crises by facing 180 million of confirmed cases with 38.9 lakh deaths across the world till end of June 2021. India alone contributes 30 million of positive cases and has lost 3.92 lakh valuable lives (data as on 24^th of June 2021 from CSSEGIS and Data (http://github.com/CSSEGISandData/COVID-19); (the number increases in each day). Bio-medical experts from all around the world are working tirelessly to limit the disease and find potential cures for this viral infection. Vaccination is the most effective strategy to prevent the spread of any viral disease. Virologists have developed some effective vaccines, but production or supply lags far behind the present demand across the globe. Plant-derived vaccines (PDVs) based on modified virus like particles (VLPs) can be a feasible alternative in this case. A summarized account about the efficacy of the first plant-derived Covid 19 vaccine, CoVLP is discussed. PDVs and VLPs are also reviewed briefly, along with their benefits and drawbacks.

Abstract Image

查看原文本刊更多论文

是否可以通过植物来确保covid - 19疫苗的供应?

任何迅速传播并跨越地理障碍的疾病都被称为大流行。在中国首次出现新冠肺炎疫情后，世界卫生组织于2020年3月宣布新型冠状病毒大流行。从那时起，COVID-19继续摧毁世界各地的人们。截至2021年6月底，全球共有1.8亿确诊病例，389万人死亡，人类文明经历了最大的危机之一。仅印度就贡献了3000万例阳性病例，并失去了39.2万条宝贵的生命(截至2021年6月24日的数据来自CSSEGIS和data (http://github.com/CSSEGISandData/COVID-19);(这个数字每天都在增加)。来自世界各地的生物医学专家正在不知疲倦地工作，以限制这种疾病，并寻找这种病毒感染的潜在治疗方法。接种疫苗是预防任何病毒性疾病传播的最有效策略。病毒学家已经开发出一些有效的疫苗，但全球范围内的生产或供应远远落后于目前的需求。在这种情况下，基于修饰的病毒样颗粒(vlp)的植物源性疫苗(pdv)可能是一种可行的替代方案。本文综述了首个植物源性Covid - 19疫苗CoVLP的有效性。本文还简要介绍了pdv和vlp，以及它们的优缺点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nucleus (India) Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

3.90

自引率

0.00%

发文量

期刊介绍： The journal publishes original, peer-reviewed articles on new and significant advances in all aspects of cell and chromosome research. Timely and substantial articles in the areas of cell biology, genetic toxicology, chromosome evolution, cytogenetics; molecular-, population- and evolutionary genetics; epigenetics; developmental and stress biology; transcriptomics, structural and functional genomics, proteomics, metabolomics, integrated omics and use of tools of bioinformatics in the areas stated herein. Studies demonstrating the use of modern approaches such as genome editing to address technological problems and/or biological questions pertaining to the research areas mentioned above are encouraged. However, the studies should be conducted with appropriate scientific rigor in the design, conduct, validity, and interpretation of results to ensure reliability and reproducibility of the data presented. The papers must be written concisely and be of interest to a broad audience. The journal also publishes comprehensive reviews on current developments and future trends in cell and chromosome research. Such articles should be authoritative, covering all the aspects of a chosen topic, and serve as a resource for students, researchers, and multidisciplinary audience. Authors are welcome to contact the Editor-in-Chief to discuss their topic of interest while preparing a prospective review article. Thematic special issues on cutting edge research in the development of the above stated areas are periodically published by the journal. Articles for such issues are commissioned by the respective topic editor/s.